This in-depth lecture and hands-on laboratory workshop (wet lab & in silica) is ideal for those research and bench scientists who are interested in a comprehensive introduction to single cell [….]
Single Cell RNA-Seq Training Workshop
RNA-Seq: Principles, Methods & Computational Analysis
This five day live remote workshop is ideal for bench and research scientists who are looking for a solid foundation in RNA-Seq, from application, experimental design and sample preparation to [….]
miRecule Inc. closes $5.7 M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophy
miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding round was led by Alexandria Venture Investments, along with Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, with additional funding coming from the Maryland Momentum Fund and the FSHD Society. This funding includes a non-dilutive $2M Phase II SBIR grant from the National Cancer Institute.
NIH spinout raises millions to attack drug-resistant cancers with RNA. It has big plans.
Gaithersburg’s miRecule Inc. has raised $5.7 million in fresh funding, CEO Anthony Saleh told us Monday, positioning the company to start human testing for its lead candidate to treat head and neck cancer.
Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer
Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer Descartes-11 specifically designed to integrate into standard treatment regimen for newly diagnosed multiple myeloma without [….]